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The incorporation of radioactive alpha tocopherol by various brain regions of wild type and apolipoprotein E (apoE)-deficient mice was
investigated. Labeled tocopherol was injected into the lateral cerebral ventricles of 11 weeks old, male mice. Radioactive cholesterol injected
simultaneously was used as an internal standard to account for experimental variability. Most areas of the brain of apoE-deficient mice took up less
of alpha tocopherol per mg of protein than wild type animals. However, specific activity of alpha tocopherol was higher in cerebellum, pons,
hypothalamus, midbrain and cerebral cortex in apoE-deficient brains than the wild type. This could be due to (a) the lower levels of alpha
tocopherol in apoE-deficient brain and (b) reductions in the clearance and transport of tocopherol (possibly mediated by apoE). Tocopherol uptake
by hippocampus was unusual since it was lower in apoE deficiency whether the data were expressed as specific activity or per mg of protein.
Nearly all of the injected alpha tocopherol remained unchanged in the brains of both apoE-deficient and wild type animals suggesting low
turnover. Overall, the current data reinforce the hypothesis that apoE is a key protein involved with the transport and/or retention of alpha
tocopherol in brain.
Published by Elsevier B.V.Keywords: Vitamin E; Apolipoprotein E; Cerebral ventricles; Cholesterol; Deficiency; Uptake1. Introduction
A number of reports in the literature suggest that the lipid
transport protein, apolipoprotein E (apoE), may play a role in the
pathogenesis of Alzheimer's disease (AD). The apo e4 allele has
been shown to be associated with the common late onset familial
and sporadic form of AD [1]. These authors found that the risk for
development of AD increased from20% to 90% and themean age
of onset of AD decreased from 84 to 68 years with increasing
number of apo e-4 alleles in 42 families with late onset AD. This
association of the risk for AD with apo e4 allele has been⁎ Corresponding author. Research Service (151), VA Medical Center,
Minneapolis, MN 55417, USA. Tel.: +1 612 467 2910; fax: +1 612 725 2084.
E-mail address: vatas001@umn.edu (G.T. Vatassery).
0925-4439/$ - see front matter. Published by Elsevier B.V.
doi:10.1016/j.bbadis.2007.04.006confirmed by many investigations [2]. Therefore, the neurobiol-
ogy of apoE is an important area of research for understanding the
pathogenesis of AD. Numerous studies have been aimed at
understanding the basic functions of apoE in brain. A few of the
functional roles of apoE include redistribution of lipids within
cells of brain, maintaining connections between synaptic regions,
and scavenging of toxins (see review [3]).
The role of apoE in lipid transport is well known and it is
conceivable that this molecule may also play a role in tissue
handling of the lipid-soluble nutrient alpha tocopherol. ApoE is
also capable of modulating the redox status of cells [4,5].
Therefore, it is reasonable to assume that apoE may be involved
in one or more aspects of the neurochemical function of vitamin
E, the most potent endogenous antioxidant in membranes. In
addition, administration of high doses of vitamin E has shown
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Recently, we reported that apoE deficiency was associated with
declines in the steady state concentrations of alpha tocopherol in
different regions of mouse brain [7]. The extent of decline in
concentration was specific to the anatomic site within brain and
was also dependent on age. This interaction of apoE with other
endogenous molecules such as vitamin E will be important for
designing potential strategies for the treatment of neurodegen-
erative disorders like Alzheimer's disease. To further elucidate
the relationship between vitamin E and apoE we conducted
additional experiments where labeled alpha tocopherol was
injected into the lateral ventricle of the brain and the
incorporation of radioactivity by different parts of the brain
was determined. Results of these experiments are presented in
this report.
2. Materials and methods
2.1. Chemicals
The chemicals used were of reagent grade purity from standard sources.
Solvents for chromatography were HPLC grade from Fisher Scientific, Itasca,
IL, USA. Alpha tocopherol and alpha tocopherolquinone were purchased from
Kodak Laboratory Chemicals, Rochester, NY, USA. Absolute ethanol was
obtained from Aaper Alcohol and Chemical Company, Shelbyville, Kentucky
and was redistilled prior to use. Most of the reagent grade chemicals were from
Sigma Chemicals, St. Louis, MO, USA. Alpha tocopherol acetate labeled with
tritium in the five position (Roche Pharmaceuticals) was saponified and
separated by HPLC prior to injection. Cholesterol, 14C labeled, was obtained
from New England Nuclear (Perkin Elmer).
2.2. Animals
The animals were housed in our AALAC-approved facilities following their
standards of care; the protocol was approved by the Subcommittee on Animal
Studies of the Minneapolis VA Medical Center. Male mice that were 11 weeks
old were used. Mice with the Apoe gene knocked out (C57BL/6J-Apoe tm1/unc)
were obtained commercially from Jackson Laboratories, Bar Harbor, Maine.
Control mice (C57 BL/6J) were also obtained from the same source. The
animals were acclimated to our animal care facilities and then placed on normal
rodent chow fed ad libitum (Diets Incorporated, PA).
2.3. Intraventricular injection of radioactive compounds
All surgical operations were made under sterile conditions. The mouse was
anesthetized using a mixture of ketamine (40 mg/kg) and xylazine (8 mg/kg) and
then secured on the stereotaxic apparatus (David Kopf Instruments, Tujunga,
CA). An incision was made along the midline (sagittal suture). The injection site
was 0.35 to 0.5 mm posterior and 1 mm lateral to the bregma (see Figs. 34 and
35 in [8]). Labeled vitamin E solution (5 μl) was used for injection. The solution
for injection contained 150,000 dpm of tritiated alpha tocopherol and
75,000 dpm of C14 cholesterol. Radioactive purities of both alpha tocopherol
and cholesterol were checked by HPLC prior to injection. The mixture for
injection was made in isotonic saline containing 0.5% BSA and 6% DMSO and
the injection volume was 5 μl. The injection was made slowly at a depth of
2.5 mm using a stopper device at the end of the syringe. After injection, the skin
incision was closed with surgical suture and the animal allowed to recover from
surgery. Forty-eight hours later, the animal was anesthetized and perfused with
cold isotonic saline. The brain was taken out and lightly rinsed with cold isotonic
saline to remove any adherent isotopic material. The excess saline was removed
gently with Kimwipe. The different brain regions were dissected out according
to the method of Glowinski and Iversen [9]. The tissues were weighed and
homogenized in 0.32 M sucrose, 10 mM HEPES, 1 mM EDTA at pH 7.4 and
stored at −70 °C and were used for the various assays.2.4. Biochemical assays: determination of alpha tocopherol
Details of the method have been reported [10]. The samples were saponified
at 60 °C after the addition of 2 ml ethanol containing 0.025%(w/v) butylated
hydroxytoluene, 0.1 ml of 30%(w/v) ascorbic acid and 1 ml 10%(w/v) KOH.
The mixture was then extracted with hexane. Part of the hexane extract was
evaporated down and the residue was redissolved in mobile phase and analyzed
by HPLC for tocopherol using the following conditions: column=ultrasphere
ODS, 5 μm, 4.6×150 mm from Beckman Instruments; mobile phase=5.5%
water in methanol with final 7.5 mM NaH2PO4; flow rate=2.5 ml/min. Alpha
tocopherol was detected electrochemically utilizing Coulochem 5100 A detector
equipped with 5011 analytical cell (detector 1 at −0.25 V and detector 2 at
+0.55 V) and 5021 conditioning cell at −0.75 V.
The metabolic fate of alpha tocopherol was also followed using this HPLC
system. In this experiment the column effluent was collected as 1-min fractions
at a column flow rate of 2 ml per min. The radioactivity in the various fractions
was counted and the counts in the tocopherol peak were determined using the
retention time for standard alpha tocopherol.
2.5. Other biochemical assays
Samples for radioactive counting were saponified and extracted with
hexane. Aliquots of the hexane extract were mixed with Ultima Gold
scintillation cocktail (Packard Biosciences, Meriden, CT) and counted on a
Packard Tri-Carb 1900-CA liquid scintillation counter. Concentration of total
proteins was determined by the Lowry technique as modified by Markwell et al.
[11].
3. Results
The tissue uptake of labeled materials can be studied after
oral, intraperitoneal, intramuscular or intravenous administra-
tion of the isotopic material. In the first experiment labeled
alpha tocopherol was injected into the tail vein. Tritium labeled
tocopherol (15 μ Curies) was employed and the isotope allowed
to equilibrate for 72 h after injection. The animals were
anesthetized and perfused with isotonic saline as described
under Methods and various tissues were dissected out. The
tissue samples were saponified and extracted with hexane. The
hexane extractable radioactivity was counted. The results are
shown in Fig. 1.
Note that the uptake by the different regions of the brain is
shown on the right side of the figure using a much smaller scale
on the Y-axis. It can be seen that radioactivity in all brain regions
was substantially lower than those in the peripheral tissues with
most of the radioactivity being associated with organs such as
liver and spleen. Even though adrenals showed high levels of
activity the total weight of the adrenals is quite small and hence
this organ contained only small amounts of the total
radioactivity. In short, most of the injected radioactivity did
not reach the brain. Therefore, the rest of the experiments
involved injection of labeled alpha tocopherol into the lateral
cerebral ventricle.
The uptakes of tritiated alpha tocopherol injected into the
right lateral ventricle of wild type and apoE-deficient mice were
then compared. Tissue samples were saponified and the
radioactivity extracted by hexane was counted. It was found
that the levels of uptake of radioactive alpha tocopherol were
quite variable between animals even though the same number of
counts was injected into the cerebral ventricle. Hence it would
be desirable to simultaneously inject a compound similar to
Fig. 1. Incorporation of radioactive alpha tocopherol by different tissues after injection of 15 micro curies of tritium labeled compound. Male mice, 11 weeks old, were
injected with tritium labeled alpha tocopherol. After 72 h the mice were anesthetized, perfused with isotonic saline and tissues were dissected out. The tissues were
saponified, extracted with hexane and the radioactivity in the hexane extract was determined. The error bars show stand error.
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other biochemical assays. It is well known that alpha tocopherol
and cholesterol have many biochemical properties in common.
Therefore, we injected a mixture of tritium labeled alpha
tocopherol and C14 labeled cholesterol into the lateral ventricle
of the brain as described under Materials and methods. The
results for the uptake of labeled cholesterol are shown in Fig. 2.
The pattern of uptake of alpha tocopherol and cholesterol
were remarkably similar confirming the basis for our selectionFig. 2. Comparison of the uptakes of labeled cholesterol injected into the right lateral
(150,000 dpm) and C14 labeled cholesterol (75,000) were injected into the right latera
were sacrificed, brains perfused, tissues dissected out, saponified, extracted with hex
S.D. of means from ten animals in each group.of cholesterol as an “internal standard” because of the known
similarity of biochemical properties of the two compounds (see
also Fig. 3 that follows). Next, we calculated the uptake of alpha
tocopherol using cholesterol uptake data to normalize alpha
tocopherol counts. An average value for cholesterol counts in
each area was calculated first. Then the cholesterol counts for
the specific area from an individual animal were divided by the
mean count and a ratio was calculated. The measured count of
alpha tocopherol radioactivity was then multiplied by this ratiocerebral ventricle of control and apoE-deficient mice. Tritiated alpha tocopherol
l ventricles of 11 weeks old mice of the respective group. After 48 h the animals
ane; the C14 radioactivity in the hexane extracts were counted. Error bars show
Fig. 3. Comparison of the corrected uptakes of labeled alpha tocopherol injected into the right lateral cerebral ventricles of normal and apoE-deficient mice. Using the
incorporation of isotopic cholesterol uptake as an internal standard the alpha tocopherol uptake data were normalized (see Results for the method of calculation). Error
bars indicate S.E. of means from ten animals in each group. Statistical significance is indicated in the figure using stars over each pair of data from wild type and apoE-
deficient animals: *Pb0.05, **Pb0.005.
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sample. The calculated counts of radioactive alpha tocopherol in
different regions of brains are shown in Fig. 3.Fig. 4. Comparison of the corrected uptakes of alpha tocopherol injected into the later
per nanomoles of endogenous alpha tocopherol. Error bars indicate S.E. Statistical si
type and apoE-deficient animals: *Pb0.05, **Pb0.005.The variability in the final results was considerably reduced
by using the correction ratios. The results show that the uptake
of alpha tocopherol was reduced in the apoE-deficient animalsal ventricle of wild type and apoE-deficient mice with the radioactivity expressed
gnificance is indicated in the figure using stars over each pair of data from wild
801G.T. Vatassery et al. / Biochimica et Biophysica Acta 1772 (2007) 797–803in hypothalamus, striatum, hippocampus and midbrain. Cere-
bellum and pons showed an increase in uptake in the apoE-
deficient animals. Similar grouping of the different brain
regions was observed in our earlier study which demonstrated
changes in tissue alpha tocopherol concentrations in apoE
deficiency [7]. In short, apoE deficiency was associated with
altered uptake of alpha tocopherol from the brain extracellular
fluid which is in equilibrium with cerebrospinal fluid (CSF).
The uptake of tocopherol may also be dependent upon the
level of alpha tocopherol present in the tissue. This can be
examined by expressing the uptake of radioactivity as a function
of the endogenous levels of alpha tocopherol. These calcula-
tions were done and the results are shown in Fig. 4.
The tocopherol uptakes by most areas of the brains of apoE-
deficient mice were higher than that of the wild type animals. This
change in relationships between the wild type and apoE-deficient
animals is partly due to the lower concentrations of alpha
tocopherol in the apoE-deficient animals. However, note that the
hippocampuswas unique in being the only site with higher uptake
of radioactive tocopherol by the wild type compared with the
apoE-deficient mice as seen in both Figs. 3 and 4. Therefore,
handling of tocopherol within the hippocampus may have some
additional unique features. In general, data presented so far show
that apoE deficiency alters the dynamics of alpha tocopherol
uptake by different areas of the brain (Figs. 3 and 4).
Radioactive tocopherol was present in very small amounts in
peripheral tissues. Fig. 4 (right side) shows the amount of
radioactivity present in liver and serum. Firstly, these results
confirm that the normal routes of absorption of CSF into the
systemic circulation were intact in all animals. Secondly, the
specific activities of alpha tocopherol in both liver and serum
were lower in apoE-deficient compared with wild type animals.
It should be noted that the concentrations of endogenous alpha
tocopherol in serum and liver were higher in the apoE-deficient
than in wild type animals: serum 5.62±0.25 and 19.5±0.83 (S.E.)
nmoles per ml: liver 17.5±0.6 and 19.90±0.76 (S.E.) nmoles per
gram, for wild type and apoE-deficient mice, respectively. Since
these concentrations appear in the denominator during calcula-
tions of specific activities it would undoubtedly have an effect
upon the final results.
The metabolic fate of radioactive alpha tocopherol in brain
regions during the experimental period of 48 h after
intraventricular injections was also examined. In this experi-
ment the brain samples from both control and apoE-deficient
animals were dissected out, and the samples saponified. Hexane
extracts were prepared and processed by HPLC as usual. The
eluents from the column were collected into individual fractions
and the radioactivity in each fraction was counted. The
radioactive counts in the alpha tocopherol peak as a percent
of the total activity were determined. The percent radioactivity
recovered in the alpha tocopherol peaks were as follows: (a)
cerebellum, hypothalamus, striatum, hippocampus and cerebral
cortex −96.1±0.97 and 94.9±0.5 (mean±SEM, n=5) for wild
type and apoE-deficient animals respectively; liver −102.5±8
and 95.6±5 (mean±SEM, n=3) for wild type and apoE-
deficient animals respectively. There were no statistically
significant differences between wild type and apoE-deficientanimals. The data show that nearly all of the radioactive alpha
tocopherol remained unchanged in the brains of both wild type
and apoE-deficient animals. This agrees with previous observa-
tions that the rate of metabolism of alpha tocopherol is quite low
in brain. Very small amounts of alpha tocopherol quinone were
found at its retention time. Oxidation of tocopherol during the
processing of samples could account for the small amounts of
activity in the quinone peak. In addition, our data also show that
apoE deficiency did not have any influence on the slow turnover
of alpha tocopherol in brain suggesting that apoE may be
involved in only the dynamics of transport of alpha tocopherol
and not in its metabolism.
4. Discussion
4.1. Intravenous injection of alpha tocopherol
Compounds can be administered through various routes in
order to study its uptake by brain. A few of the most commonly
used methods are oral, intramuscular or intravenous delivery. In
the first experiment we studied the uptake of labeled alpha
tocopherol after intravenous administration. Our data showed
that the level of radioactivity (per gram tissue) in the different
areas of the brain was less than a few percent of that found in
liver or adrenals (Fig. 1). Gallo-Torres [12] has summarized his
extensive studies on the tissue distribution of radioactive
tocopherol after intragastric and intravenous routes of admin-
istration. He observed that only 0.03% of total radioactivity was
found in brain 12 h after oral dosing. When administered
intravenously the brain was found to contain only 0.22% of the
radioactivity injected. Thus our study and that of Gallo-Torres
indicate that the uptake of tocopherol radioactiviy by brain is
quite low. Interestingly, the steady state concentration of alpha
tocopherol in brain is very similar to that of other tissues such as
the liver even though uptake by brain is much smaller than that
by liver. This suggests that tocopherol entering brain has a slow
turnover rate compared with other organs. Neither oral nor
intravenous administration of radioactive tocopherol result in
significant uptake of activity by the brain and the techniques are
associated with substantial wasting of the radioactive com-
pound. This led us to the use of intracerebroventricular injection
of labeled alpha tocopherol.
4.2. Uptake of radioactive alpha tocopherol by different
regions of the brain after intracerebroventricular injection
First the uptake data from wild type animals (filled bars in
Fig. 3) will be considered. The different regions of the brain
incorporated varying amounts of radioactive alpha tocopherol
that was injected into the lateral ventricle. A variety of factors
determine the level of incorporation of radioactivity by different
regions with two physical factors playing major roles. Firstly,
the larger the ventricular surface area that is in contact with CSF
the higher will be the uptake by that region. In fact, this may be
one reason for the high levels of uptake by hippocampus.
Interestingly, the latter region is important on behavioral
grounds since it is involved with memory function.
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considered. We observed that after hippocampus the next
highest level of incorporation of radioactive alpha tocopherol
was in the midbrain. This may be explained partially by the fact
that CSF flows to the third ventricle and the cerebral aqueduct
from the lateral ventricles. At this point CSF is still in contact
with internal surfaces of the brain parenchyma where the CSF
flows into interstitial space across ependymal cells which have
leaky gap junctions permeable to macromolecules [13].
Ultimately, CSF flows to the fourth ventricle and then out via
the foramina of Magende and Luschka into the basilar cisterns.
This may account for the moderate levels of uptake by pons and
cerebellum. Distribution of label into the subarachnoid space
surrounding the spinal cord and finally the subarachnoid space
overlaying brain surfaces occurs last. Samples of cortex which
contact CSF only at the brain surface showed low alpha
tocopherol uptake. Biomolecules in the subarachnoid space
diffuse directly across pial surfaces and through Virchow–
Robin spaces into the interstitial space [14]. Frontal cortex
showed one of the lowest levels of uptake since this will be the
region exposed to CSF towards the end of its path through brain
prior to its absorption on the superior surface of the brain at the
arachnoid granulations.
4.3. Role of apoE in the transport and uptake of tocopherol
from CSF into the brain
The above two paragraphs takes into account only physical
factors that may control uptake of radioactive tocopherol by
different areas of the brain. Obviously, there will be receptor-
mediated as well as passive transport events involved in the
uptake. CSF is in equilibrium with the extracellular fluid of the
brain. Therefore, substances injected into the ventricular fluid
would encounter only small barriers for transport into brain. For
example, studies involving radionuclide cysternography show
that absorption of CSF can occur throughout the brain
parenchyma at numerous sites [15]. It should also be stressed
that apoE is a major apolipoprotein in CSF and its CSF
concentration is about 3% of the plasma concentration [16].
Thus apoE is well suited to be involved with tocopherol
transport between brain cells and the extracellular fluid. Entry of
labeled tocopherol from extracellular fluid into neurons and glia
could be mediated by transporters and/or by diffusion across
plasma membrane. Studies show that transport of plasma lipids
from blood to brain may involve fast dissociation of lipid from
protein complexes followed by cellular uptake [17]; such
processes may be operating in the transfer of protein-bound
tocopherol from CSF to brain parenchyma. The final pattern of
uptake of labeled tocopherol after ventricular injection would be
expected to depend upon one or more of the factors noted so far.
Next, one can consider the tocopherol uptake data that was
converted to specific activity by expressing radioactivity per
nanomoles of alpha tocopherol (Fig. 4). A comparison of these
data with those where uptake data are expressed per mg protein
shows some common features and a few differences (See Figs. 3
and 4). The apoE-deficient animals incorporated more tocopherol
in cerebellum and pons whereas the uptake by hippocampus waslower when compared with the wild type animals in both
Figs. 3 and 4. It is unknown whether different modes of uptake of
alpha tocopherol occur in hippocampus compared with cerebel-
lum and pons. Note that the radioactive uptake calculated as dpm
per nanomole of alpha tocopherol in most regions of the brain
except hippocampus and striatum show an increase in alpha
tocopherol specific activity in apoE-deficient mice when
compared with the wild type animals (Fig. 4). It can be safely
assumed that all physical factors that could affect uptake remain
the same for both the wild type and apoE-deficient mice. One
factor that would cause the specific activity to go up in the case of
apoE-deficient tissue is the lower concentrations of alpha
tocopherol in the apoE-deficient brains as reported by us [7].
Another possible reason for the increase in specific activity in
apoE-deficient animals is that the lack of apoE may be impeding
the normal mode of transport of tocopherol within the brain
resulting in lower clearance of labeled tocopherol in most areas of
the brain. Reports suggest that nascent lipoprotein particles
secreted by astrocytes contain apoE and it has been proposed that
they take part in cholesterol transport within the brain [18];
tocopherol transport may follow similar routes. If this were the
case, tocopherol injected as an albumin complex would be cleared
from the interstitial fluid to a lesser extent in apoE-deficient mice
than in controls. Consequently, we would expect tocopherol
specific activity to be higher in many areas of the apoE-deficient
brains and this was what we observed (Fig. 4). Interestingly,
hippocampus in apoE-deficient animals had lower uptake of
labeled tocopherol whether the data were expressed per mg
protein (Fig. 3) or as specific activity (Fig. 4). Hence hippocampus
may be utilizing a more complex process for handling tocopherol.
With all brain regions it is also possible that molecules that
normally accept alpha tocopherol at the plasma membrane site
may have been altered in concentration, composition or structure
in response to apoE deficiency. One example of such amolecule is
scavenger receptor BI; a deficiency of this receptor has been
shown to cause declines in brain levels of tocopherol [19].
Accumulation of radioactivity in the periphery is also altered
by apoE deficiency (Fig. 4). As expected, the level of activity
was quite small both in liver and serum when compared with the
activity in brain. Interestingly, the specific activity levels in the
apoE-deficient animals were lower than those in the wild type.
This trend is opposite of that found in most of brain regions. It is
noteworthy that the concentrations of endogenous alpha
tocopherol go up in the periphery in response to apoE
deficiency whereas the opposite is the case with brain regions.
Regardless of the direction of change, the data show that apoE
deficiency was associated with an alteration in the dynamics of
alpha tocopherol uptake in peripheral tissues as well.
4.4. Conclusions
Intravenously injected alpha tocopherol entered the brain to a
much lesser extent than the peripheral tissues such as liver.
Nonetheless, brain alpha tocopherol levels at steady state were
comparable to those of peripheral tissues indicating that
tocopherol turnover rate in brain is much lower than in peripheral
tissues. Our finding that most alpha tocopherol injected into brain
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species in both wild type and apoE-deficient animals also
suggests low rates of turnover of the compound. Earlier studies
using very different techniques have also shown low turnover rate
of tocopherol in the brain [20]. Furthermore, apoE deficiency did
not change the metabolism of alpha tocopherol. In the current
investigation, labeled tocopherol was injected into the lateral
cerebral ventricles since the uptake after intravenous injectionwas
quite low. Data from radioactive cholesterol injected simulta-
neously were used as internal standard to reduce the experimental
variability during ventricular injection. Examination of data from
control animals showed that (a) areas with larger surface areas in
contact with CSF took up larger amounts of alpha tocopherol
(e.g., hippocampus) and (b) areas that are close to the lateral
ventricle also took up more activity possibly because these
regions are more proximal in the pathway of flow of CSF (e.g.,
hippocampus). ApoE deficiency resulted in increases in uptake
and retention of radioactive vitamin E when data were expressed
as dpm per nanomole of alpha tocopherol. This indicates that
apoE may be involved in the normal processing of vitamin E in
brain and apoE deficiency causes an impaired clearing of alpha
tocopherol. In any case, the uptake and retention of alpha
tocopherol by different regions of the brain were clearly
modulated by apoE deficiency. Alpha tocopherol was incorpo-
rated less in the hippocampus from apoE-deficient brains whether
the uptake was expressed as units per mg protein or per nanomole
of alpha tocopherol. This suggests that the handling of tocopherol
by the hippocampus may have some unique features. Using
literature reports and the data presented we propose that a
complex of proteins including apoE may be involved in the
transport of vitamin E across the brain cellular membranes. The
current data along with our previous publication [7] provide
additional evidence illustrating a functional interaction between
apolipoprotein E and vitamin E in mammalian brain.
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